miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

Abstract Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC). However, most NSCLC patients inevitably develop gefitinib resistance, and the mechanisms underlying this resistance are not ful...

Full description

Bibliographic Details
Main Authors: Xiaonian Cao, Senyan Lai, Fayong Hu, Guodong Li, Guihua Wang, Xuelai Luo, Xiangning Fu, Junbo Hu
Format: Article
Language:English
Published: Nature Publishing Group 2017-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-017-01153-0

Internet

https://doi.org/10.1038/s41598-017-01153-0

Similar Items